Adipotide (FTPP) vs AOD-9604
Adipotide (FTPP) (Pro-apoptotic peptidomimetic (prohibitin-targeting)) and AOD-9604 (Modified GH-fragment peptide) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Adipotide (FTPP) | AOD-9604 |
|---|---|---|
| Compound class | Pro-apoptotic peptidomimetic (prohibitin-targeting) | Modified GH-fragment peptide |
| Research category | Metabolic & Mitochondrial | Metabolic & Mitochondrial |
| Length (amino acids) | Not documented | 16 amino acids |
| Molecular weight | ~2611 g/mol (approx. C152H252N44O42) | ~1815 g/mol |
| Half-life | Not documented | ~20-40 minutes (reported) |
| Origin | Adipotide (also called FTPP, prohibitin-targeting peptide-1) is a synthetic peptidomimetic combining a prohibitin-targeting sequence (CKGGRAKDC) with a pro-apoptotic amphipathic domain (KLAKLAK)2 via a linker. It was developed as an experimental agent to target the vasculature of white adipose tissue. | AOD-9604 is a synthetic, stabilized analog of the C-terminal lipolytic region (residues 176-191) of human growth hormone, developed in the 1990s at Monash University. It adds an N-terminal tyrosine to the native fragment and retains the intramolecular disulfide bridge between the two cysteine residues. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Adipotide (FTPP) works
The CKGGRAKDC domain binds a prohibitin/ANXA2 receptor complex found on the endothelium (blood vessels) supplying white adipose tissue. Once localized, the D(KLAKLAK)2 domain disrupts mitochondrial membranes and triggers apoptosis, ablating the blood supply to fat depots. In animal studies this produced rapid loss of adipose tissue.
How AOD-9604 works
AOD-9604 corresponds to the C-terminal fragment of GH that carries the hormone's lipolytic (fat-metabolizing) activity while lacking the regions responsible for GH's growth-promoting and insulin-antagonizing effects. In preclinical models it has been reported to stimulate lipolysis and inhibit lipogenesis. It does not act as a full growth hormone and reportedly does not raise IGF-1 or affect blood glucose in the manner of intact GH.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Adipotide (FTPP)
AOD-9604
What sets each apart
Adipotide (FTPP)
Unlike the lipolytic GH fragments, adipotide does not stimulate fat metabolism; it destroys the blood vessels feeding fat tissue via a targeted pro-apoptotic mechanism.
AOD-9604
Unlike full-length GH or GH secretagogues, AOD-9604 targets only the lipolytic C-terminal region; unlike the raw HGH Fragment 176-191, it carries an extra N-terminal tyrosine intended to improve stability.
Frequently asked questions
What is adipotide (FTPP)?
Adipotide, also called prohibitin-targeting peptide-1 (FTPP), is a synthetic peptidomimetic with two domains: a homing motif (CKGGRAKDC) that targets white-adipose-tissue vasculature and a pro-apoptotic (KLAKLAK)2 moiety. It is studied as a targeted anti-obesity research agent that acts on the blood supply of fat tissue rather than on fat cells directly.
How does adipotide work mechanistically?
The homing peptide is reported to bind a prohibitin/annexin A2 complex on endothelial cells feeding white adipose tissue; the attached pro-apoptotic sequence then triggers apoptosis in those vessels. Disrupting the adipose blood supply causes the fed fat cells to regress, altering lipid uptake, glucose handling, and adipose signaling in models.
What research supports adipotide?
In a primate study, obese rhesus monkeys were reported to lose about 11% of body weight over 28 days with roughly 39% reduction in fat deposits. Rodent work reported similar targeted fat-mass loss. Because its mechanism affects vasculature, kidney-related effects have been a noted concern in the preclinical literature.
What is AOD-9604 and what class of compound is it?
AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal region (residues 176-191) of human growth hormone, modified with an added N-terminal tyrosine and a disulfide bridge between its two cysteine residues. It is studied as a lipolytic (fat-metabolism) peptide that appears to isolate the fat-mobilizing activity of GH. It is a research peptide, not an approved therapeutic in most jurisdictions.
How does AOD-9604 differ from unmodified HGH Fragment 176-191?
AOD-9604 is a stabilized analog of HGH Fragment 176-191: it adds a tyrosine residue at the N-terminus of the native fragment. This modification was engineered in preclinical work to improve metabolic stability and lipolytic activity relative to the raw fragment. Both are studied for fat metabolism, but AOD-9604 is the more characterized, stabilized version.
Does AOD-9604 raise IGF-1 or affect blood glucose in research models?
In preclinical models, AOD-9604 was reported to stimulate lipolysis and inhibit lipogenesis without the growth-promoting or diabetogenic effects associated with full-length growth hormone. Studies indicate it does not meaningfully elevate IGF-1 or disturb glucose handling in the models examined. These findings are from research settings and are not clinical guarantees.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.